

K010499

MAY - 3 2001

## 3.0 Summary of Safety and Effectiveness Information

SPONSOR:

Synthes (USA)

1690 Russell Road Paoli, PA 19301 (610) 647-9700

Contact: Thomas M. Maguire

**DEVICE NAME:** 

Midface Distractor

CLASSIFICATION: PREDICATE DEVICE:

Class II, 21 CFR 872.4760: Bone plate

Cohen Distractor (Howmedica Leibinger Inc.)

**DEVICE DESCRIPTION:** 

The Synthes Midface Distractor is a craniofacial distraction device consisting of two telescoping components with attached footplates. The device is intended to be placed subcutaneously, with an anterior footplate fastened to the lateral orbital rim, extending down to the maxilla and spanning the zygomaticomaxillary suture; and a posterior footplate fastened to the temporal region of the cranium. The plates are fixed to the bone through unthreaded screw holes using 1.5 mm or 2.0 mm Cortex screws.

INTENDED USE:

For use in adult and pediatric populations for the treatment of cranial or midface conditions for which reconstructive osteotomy and segment advancement are indicated. This includes conditions such as syndromic craniosynostosis and midfacial retrusion. The device is intended to provide temporary stabilization and gradual lengthening of the cranial or midfacial bones.

MATERIAL:

Titanium Alloy, Titanium, Chromium Cobalt



MAY - 3 2001

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Mr. Thomas M. Maguire Project Leader of Regulatory Affairs Synthes (USA) 1101 Synthes Avenue Monument, Colorado 80132

Re: K010499

Trade/Device Name: Synthes (USA) Midface Distractor

Regulation Number: 872.4760

Regulatory Class: II Product Code: JEY

Dated: February 20, 2001 Received: February 21, 2001

## Dear Mr. Maguire:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the <u>Code of Federal Regulations</u>, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>. Please note:

this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4692. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".

Sincerely yours

Timothy A. Ulatowsk

Director

Division of Dental, Infection Control and General Hospital Devices Office of Device Evaluation Center for Devices and Radiological Health

## **SYNTHES**°

K010499

2.0	Indications for Use Statement	Page _1 of1
510(k)	x) Number (if known):	
Devic	ce Name: Synthes (USA) Midface Distractor	
Indica	ations/Contraindications:	
recons	ase in adult and pediatric populations for the treatment of cranastructive osteotomy and segment advancement are indicated romic craniosynostosis and midfacial retrusion. The device is lization and gradual lengthening of the cranial or midfacial be	intended to provide temporary
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)		
Concurrence of CDRH, Office of Device Evaluation (ODE)		
	cription UseOR 21 CFR 801.109)	Over-The-Counter Use_
	Sum Punges	
	িল্লাকা Sign-Off) mion of Dental, Infection Control, িল্লালো Hospital Devices বিল্লালোক ত্রিতি (প্র	